

Japan bags new opportunity to improve healthcare system

27 February 2023 | News

Omi Medical Center signs partnership agreement with TriNetX to increase participation in multi-national clinical trials



Omi Medical Center, a part of the Seikoukai Social Medical Corporation and one of Japan's leading institutions in the use of advanced medical technologies, has announced it is partnering with US-based TriNetX to increase its exposure and participation in multi-national industry-sponsored clinical trials.

"The use of Japanese pharmaceuticals has dropped from 20% to less than 10% of the global market over the past 30 years," said Atsuyuki Wada, Special Assistant to the President and Director, Clinical Research Center, Omi Medical Center. "Japan also ranks around 30th in the number of global clinical trials, and as a result clinicians in the country have fewer opportunities to learn about innovative treatments, medicines, and the benefits they can bring to patients. One of our goals of joining the TriNetX Network is to reverse this trend and help Japanese patients suffering from a wide variety of challenging diseases."

Omi Medical Center is one of the institutions in western Japan that offers state-of-the-art medical and surgical care in the fields of cardiovascular, obstetrics and gynecology, gastroenterology, and head and neck.

The center provides a wide range of services including emergency medicine, community healthcare, oncology-related community support, and disaster medicine to the people of the surrounding area, which is experiencing population growth.

"The partnership agreement between Omi Medical Center and TriNetX will be a meaningful opportunity to improve Japan's healthcare system as a whole," continued Wada. "TriNetX will provide Omi Medical Center with the opportunity to join a global community of pharmaceutical companies and healthcare organisations. This will allow us to strengthen our collaborations with other peer institutions, gain opportunities to participate in clinical trials, and ensure the safe and legal secondary use of real-world data for the benefit of our patients."